Salvavidas Pharmaceutical Pvt Ltd is a leading supplier and exporter of ursodeoxycholic acid API.

Ursodeoxycholic acid

A byproduct of intestinal bacterial metabolism is ursodeoxycholic acid API. This bile acid is regarded as secondary. Primary bile acids, the other form of bile acid, are created by the liver and then kept in the gallbladder. Bacteria found in the intestine can convert primary bile acids that are released into the large intestine into secondary bile acids.

The metabolism of dietary fat is aided by both varieties of bile acids. By decreasing the rate at which the gut can absorb cholesterol and acting to break down micelles, which contain cholesterol, ursodeoxycholic acid API controls cholesterol levels. This characteristic makes ursodeoxycholic acid useful for the non-surgical treatment of gallstones.

By allowing bile to move more easily through the liver and shielding liver cells, ursodeoxycholic acid lowers high liver enzyme levels. The anticholelithic is the primary mechanism. Although the precise mechanism of ursodiol’s anticholelithic activity is not fully understood, it is believed that the medication is concentrated in bile and lowers biliary cholesterol by limiting its intestine absorption as well as hepatic synthesis and release of cholesterol. Because of the decreased cholesterol saturation, the cholesterol in gallstones can gradually dissolve, leading to the eventual disintegration of the stones.